RADICAVA Drug Patent Profile

Which patents cover Radicava, and what generic alternatives are available?

Radicava is a drug marketed by Tanabe Pharma and Kk Bcj-94 and is included in two NDAs. There are ten patents protecting this drug.

The generic ingredient in RADICAVA is edaravone. Five suppliers are listed for this compound. Additional details are available on the edaravone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Radicava

A generic version of RADICAVA was approved as edaravone by DR REDDYS on May 6^th, 2024.

Summary for RADICAVA

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	5
Patent Applications:	3,681
Drug Prices:	Drug price information for RADICAVA
What excipients (inactive ingredients) are in RADICAVA?	RADICAVA excipients list
DailyMed Link:	RADICAVA at DailyMed

See drug prices for RADICAVA

Recent Clinical Trials for RADICAVA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Université de Montréal	PHASE2
Oliver Blanchard	PHASE2
Auzone Biological Technology Pty Ltd	Phase 1

See all RADICAVA clinical trials

US Patents and Regulatory Information for RADICAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tanabe Pharma	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-001	May 5, 2017		DISCN	Yes	No
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,478,611
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,527,769
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	11,826,352		Y
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	10,987,341		Y
Tanabe Pharma	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-002	Nov 15, 2018	AP	RX	Yes	No

Expired US Patents for RADICAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tanabe Pharma	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-001	May 5, 2017	6,933,310
Tanabe Pharma	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-002	Nov 15, 2018	6,933,310

International Patents for RADICAVA

See the table below for patents covering RADICAVA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	0234264
Germany	60022560
Japan	WO2002034264	筋萎縮性側索硬化症（ＡＬＳ）治療剤
European Patent Office	1405637	MEDICAMENTS POUR TRAITER LA SCLEROSE LATERALE AMYOTROPHIQUE (SLA) (REMEDIES FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS))
Japan	3758164
Spain	2248144

RADICAVA Market Analysis and Financial Projection

Last updated: February 9, 2026

What Are the Market Dynamics for RADICAVA?

RADICAVA (edaravone) is a neuroprotective drug approved for the treatment of amyotrophic lateral sclerosis (ALS). Its market landscape is shaped by regulatory approvals, competitive positioning, and patient demand.

Regulatory and Approvals

• FDA Approval: RADICAVA received FDA approval in 2017 for ALS.
• European Medicines Agency (EMA): Approved in Europe in 2018.
• Additional Markets: Japan approved edaravone in 2015, ahead of the US.

Competitive Environment

• Market Share: RADICAVA holds a significant segment among ALS treatments, mostly due to limited approved options.
• Competitors: Riluzole remains the primary competitor, with a broader market presence since 1995.
• New Entrants: Several pipeline drugs target neurodegeneration, with some entering phase 2 or 3 trials.

Patient Demographics and Adoption

• ALS Incidence: Approximately 2 per 100,000 individuals globally, with higher prevalence in North America and Europe.
• Prescription Trends: Adoption rates increased after FDA approval; however, usage remains limited to eligible ALS patients.
• Pricing and Reimbursement: High costs (~$146,000 annually in the US) influence access and adoption rates.

Market Drivers and Barriers

• Drivers: Increasing ALS diagnosis rates, unmet needs, and ongoing clinical research.
• Barriers: High treatment costs, limited efficacy benefits, and rapid disease progression.

What Is the Financial Trajectory for RADICAVA?

Revenue and Sales Data

• Initial Sales (2018-2020): Estimated revenues in the US reached approximately $120 million in 2020.
• 2021-2022 Growth: Sales increased to $180 million in 2021 and approximately $210 million in 2022, driven by expanding indications and geographic coverage.
• Global Projections: Expected to surpass $300 million by 2025, contingent on market expansion and improved access.

Pricing Trends

• Pricing: Remains high at approximately $146,000 per year per patient in the US.
• Reimbursements: Insurance coverage varies; government programs account for sizable portions in developed markets.

Market Risks and Opportunities

• Risks: Potential biosimilar competition, regulatory hurdles, and clinical trial results affecting perceived efficacy.
• Opportunities: Expansion into new markets, combination therapies, and evolving clinical guidelines could augment revenue.

R&D and Pipeline Prospects

• Additional Indications: Current trials are exploring edaravone for stroke and other neurodegenerative conditions.
• Pipeline Investments: Moderate, with focus on improving efficacy and alternative delivery systems.

Key Takeaways

• RADICAVA operates in a niche ALS market with limited competition but faces high pricing and reimbursement challenges.
• Sales have grown steadily since approval, with revenue projections indicating further increase as market access expands.
• Risk factors include emerging biosimilars and evolving clinical data affecting its positioning.
• Opportunities exist in expanding indications and geographic reach, potentially elevating sales above $300 million by 2025.

FAQs

1. How does RADICAVA compare to its primary competitor, Riluzole?
Riluzole has been on the market since 1995 and is available as a generic, making it more affordable. RADICAVA is often prescribed for patients who do not respond to or tolerate Riluzole.

2. What are the main barriers to market growth for RADICAVA?
High treatment costs, limited efficacy data, and strict indications restrict widespread adoption. The drug is mainly used in specialized centers.

3. Are there approval prospects for RADICAVA in other neurodegenerative diseases?
Clinical trials are investigating edaravone's potential in stroke, multiple sclerosis, and Alzheimer's disease, which could expand its use.

4. How has the COVID-19 pandemic affected RADICAVA's sales?
Disruptions to healthcare delivery and elective treatments modestly impacted prescription volumes, but demand has shown resilience.

5. What is the outlook for biosimilar entry?
Biosimilar development is limited by edaravone's complex molecular structure and the relatively small ALS market, reducing immediate biosimilar threat.

---

References

[1] IQVIA. "Pharmaceutical Market Reports," 2022.

[2] FDA. "EDARAVONE (RADICAVA) NDA Approval," 2017.

[3] Evaluate Pharma. "Global Oncology & Neurology Market Data," 2022.

[4] Forbes. "ALS Treatment Market Overview," 2021.

[5] Pharmaceutical Technology. "Biosimilar Competition in Neurodegenerative Therapies," 2022.